Caloxa 50 mg Film coated tablets

Caloxa 50 mg Film coated tablets

S4
PDF Leaflet Revision Date: 31 January 2023

API: Bicalutamide | Company: Eurolab

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of advanced prostate cancer.

Dosage (summary)

One tablet (50 mg) once daily.

Special Populations

  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Not established; contraindicated in pregnant or breastfeeding women.

Key Drug Interactions

  • LHRH analogues
  • Ketoconazole
  • Cimetidine
  • Warfarin

Contraindications

  • Females
  • Children
  • Pregnant women
  • Breastfeeding mothers
  • Hypersensitivity

Common side effects

  • Anaemia
  • Dizziness
  • Somnolence
  • Myocardial infarction
  • Hypertension

Counselling Points

  • Monitor for liver function changes.
  • Avoid driving if experiencing somnolence.
  • Report any severe side effects.

Serious warnings

  • Hepatic impairment may increase toxicity.
  • Periodic liver function testing recommended.
Important Disclaimer

The Caloxa 50 mg Film coated tablets professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites